Neuroblastoma (NB) the most frequent extra cranial solid tumor, with only 10% survival after systemic recurrence accounts for 15% of all childhood cancer fatalities. Recurring tumor may arise from remnant cells of neoplasm that have escaped therapeutic intervention and later become visible at original site. We have shown that inhibition of NFkB enhanced radiotherapy (RT)-induced cell-death in NB cells. To that note, identifying and delivering compounds that selectively targets NFkB would prove beneficial in mitigating NB relapse/metastasis. We hypothesize that: (1) NB cells that survive RT may result in the development of survival advantage mediated by persistent NFkB activation through NFkB-TNFalpha positive feed back cycle (PFC). This response could lead to clonal expansion'and tumor recurrence. (2) RT-induced inhibition of eNOS regulated NO activates MMP9 dependent transactivation of NFkB, which in turn modulates MMP/TIMP balance that leads to NB progression/metastasis and (3) Selective, two dimensional targeting of RT-induced NFkB with EF24-loaded immunoliposomes targeting GD2 (EF24-IL=>GD2) may result in complete prevention of NB relapse/metastasis. Using NB xenograft model, we will determine:
(Aim 1) whether RT could initiate PFC leading to a persistent activation of NFkB and subsequent survival advantage and initiation of clonal expansion.
(Aim 2) whether IR regulated eNOS dependent NO activates MMP9 and to study its role in NFkB dependent MMP/TIMP imbalance, NB progression and metastasis.
(Aim 3) the efficacy of EF24-IL=>GD2 in inhibiting IR-induced NFkB-TNFa cross signaling dependent persistent activation of NFkB mediated survival advantage and clonal expansion and (Aim 4) the potential effect of EF24-1L=>GD2 in IR-inhibited eNOS-NO dependent MMP9 induced NFkB mediated NB progression and metastasis. On completion, this study will provide insight into the orchestration of NFkB after RT and its downstream response. Most importantly, this study could lead to the development of a """"""""deliverable"""""""" to test in clinical settings to mitigate local failure and metastasis, that could lead to a positive impact on NB patients.

Public Health Relevance

This study will not only throw light on the molecular blue print that underlies the neuroblastoma relapse, progression and metastasis;this study will also delineate the clinical efficacy of EF24, the analogue of known anti-oxidant curcumin and more importantly the targeted delivery of this compound precisely to NB sites. Achieving this in pre-clinical model would lead to test the approach in clinical settings, and this would shift a huge archetype in current practice that could positively impact innumerable NB patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-02
Application #
8539826
Study Section
Special Emphasis Panel (ZRR1-RI-4)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$212,771
Indirect Cost
$69,008
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Bastian, Anja; Matsuzaki, Satoshi; Humphries, Kenneth M et al. (2017) AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1? stabilization. Cancer Lett 388:149-157
Pearsall, Elizabeth A; Cheng, Rui; Zhou, Kelu et al. (2017) PPAR? is essential for retinal lipid metabolism and neuronal survival. BMC Biol 15:113
Boswell-Casteel, Rebba C; Hays, Franklin A (2017) Equilibrative nucleoside transporters-A review. Nucleosides Nucleotides Nucleic Acids 36:7-30
Griffith, James; Andrade, Daniel; Mehta, Meghna et al. (2017) Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep 37:2382-2390
Banerjee Mustafi, Soumyajit; Chakraborty, Prabir Kumar; Dwivedi, Shailendra Kumar Dhar et al. (2017) BMI1, a new target of CK2?. Mol Cancer 16:56
Muralidharan, Ranganayaki; Babu, Anish; Amreddy, Narsireddy et al. (2017) Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther 16:1470-1486
Nguyen, Charles B; Houchen, Courtney W; Ali, Naushad (2017) APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Exp Biol Med (Maywood) 242:242-249
Chakraborty, Prabir K; Mustafi, Soumyajit Banerjee; Xiong, Xunhao et al. (2017) MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun 8:14634
Aravindan, Sheeja; Somasundaram, Dinesh Babu; Kam, Kwok Ling et al. (2017) Retinal Degeneration Protein 3 (RD3) in normal human tissues: Novel insights. Sci Rep 7:13154
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2017) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113

Showing the most recent 10 out of 54 publications